Valley Fever Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major valley fever markets are expected to exhibit a CAGR of 3.53% during 2024-2034.
The valley fever market has been comprehensively analyzed in IMARC's new report titled "Valley Fever Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Valley fever, also called coccidioidomycosis, is a type of fungal infection caused by the coccidioides fungus, which grows in arid soil and dirt. Some people may have no indications at all, while others may develop flu-like symptoms, such as fever, cough, headache, fatigue, etc. However, many individuals may experience more worsening indications, including chest pain, shortness of breath, night sweats, headaches, muscle aches, joint pain, etc. In rare cases, the infection can spread to other parts of the body, such as the skin, bones, and brain, causing severe symptoms like skin lesions, meningitis, or even death. The diagnosis of valley fever requires a combination of the patient's travel history, clinical features, and a physical examination. A blood test can also be utilized to determine the presence of antibodies or antigens in the body. The healthcare provider may perform numerous imaging studies, such as chest X-rays, computerized tomography scans, etc., that provide lung pictures to visualize a potentially serious complication. In severe cases, a biopsy of the affected site is recommended for a detailed investigation and confirmation of the illness.
The increasing incidence of exposure to fungus spores that thrive in soil disruptions caused by human or animal activity, including construction sites and farming operations, is primarily driving the valley fever market. In addition to this, the rising prevalence of various associated risk factors, such as advancing age, weakened immune system, occupational hazards, etc., is also bolstering the market growth. Furthermore, the widespread adoption of antifungal medications, including fluconazole and itraconazole, for treating the ailment is acting as another significant growth-inducing factor. These pharmacological agents work by inhibiting the synthesis of a vital part of the fungal cell membrane that reduces the fungus's ability to replicate and prevents disease progression in patients. Additionally, numerous key players are making extensive investments in R&D activities to introduce immunomodulatory therapies, such as interferon-gamma or granulocyte-macrophage colony-stimulating factor (GM-CSF), which can help to boost the immune system's response to the infection. This, in turn, is further creating a positive outlook for the market. Moreover, the ongoing development of a two-dose human vaccine for the condition, since it encourages an immune response against the fungus and provides long-term protection from the infection, is expected to drive the valley fever market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the valley fever market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for valley fever and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the valley fever market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the valley fever market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the valley fever market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current valley fever marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the valley fever market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the valley fever market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the valley fever market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of valley fever across the seven major markets?
What is the number of prevalent cases (2018-2034) of valley fever by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of valley fever by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with valley fever across the seven major markets?
What is the size of the valley fever patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of valley fever?
What will be the growth rate of patients across the seven major markets?
Valley Fever: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for valley fever drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the valley fever market?
What are the key regulatory events related to the valley fever market?
What is the structure of clinical trial landscape by status related to the valley fever market?
What is the structure of clinical trial landscape by phase related to the valley fever market?
What is the structure of clinical trial landscape by route of administration related to the valley fever market?
The valley fever market has been comprehensively analyzed in IMARC's new report titled "Valley Fever Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Valley fever, also called coccidioidomycosis, is a type of fungal infection caused by the coccidioides fungus, which grows in arid soil and dirt. Some people may have no indications at all, while others may develop flu-like symptoms, such as fever, cough, headache, fatigue, etc. However, many individuals may experience more worsening indications, including chest pain, shortness of breath, night sweats, headaches, muscle aches, joint pain, etc. In rare cases, the infection can spread to other parts of the body, such as the skin, bones, and brain, causing severe symptoms like skin lesions, meningitis, or even death. The diagnosis of valley fever requires a combination of the patient's travel history, clinical features, and a physical examination. A blood test can also be utilized to determine the presence of antibodies or antigens in the body. The healthcare provider may perform numerous imaging studies, such as chest X-rays, computerized tomography scans, etc., that provide lung pictures to visualize a potentially serious complication. In severe cases, a biopsy of the affected site is recommended for a detailed investigation and confirmation of the illness.
The increasing incidence of exposure to fungus spores that thrive in soil disruptions caused by human or animal activity, including construction sites and farming operations, is primarily driving the valley fever market. In addition to this, the rising prevalence of various associated risk factors, such as advancing age, weakened immune system, occupational hazards, etc., is also bolstering the market growth. Furthermore, the widespread adoption of antifungal medications, including fluconazole and itraconazole, for treating the ailment is acting as another significant growth-inducing factor. These pharmacological agents work by inhibiting the synthesis of a vital part of the fungal cell membrane that reduces the fungus's ability to replicate and prevents disease progression in patients. Additionally, numerous key players are making extensive investments in R&D activities to introduce immunomodulatory therapies, such as interferon-gamma or granulocyte-macrophage colony-stimulating factor (GM-CSF), which can help to boost the immune system's response to the infection. This, in turn, is further creating a positive outlook for the market. Moreover, the ongoing development of a two-dose human vaccine for the condition, since it encourages an immune response against the fungus and provides long-term protection from the infection, is expected to drive the valley fever market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the valley fever market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for valley fever and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the valley fever market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the valley fever market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the valley fever market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current valley fever marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the valley fever market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the valley fever market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the valley fever market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of valley fever across the seven major markets?
What is the number of prevalent cases (2018-2034) of valley fever by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of valley fever by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with valley fever across the seven major markets?
What is the size of the valley fever patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of valley fever?
What will be the growth rate of patients across the seven major markets?
Valley Fever: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for valley fever drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the valley fever market?
What are the key regulatory events related to the valley fever market?
What is the structure of clinical trial landscape by status related to the valley fever market?
What is the structure of clinical trial landscape by phase related to the valley fever market?
What is the structure of clinical trial landscape by route of administration related to the valley fever market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 VALLEY FEVER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 VALLEY FEVER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 VALLEY FEVER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 VALLEY FEVER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 VALLEY FEVER - UNMET NEEDS
10 VALLEY FEVER - KEY ENDPOINTS OF TREATMENT
11 VALLEY FEVER - MARKETED PRODUCTS
11.1 List of Valley Fever Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 VALLEY FEVER - PIPELINE DRUGS
12.1 List of Valley Fever Pipeline Drugs Across the Top 7 Markets
12.1.1 VT 1598 - Mycovia Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. VALLEY FEVER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. VALLEY FEVER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 VALLEY FEVER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Valley Fever - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Valley Fever - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Valley Fever - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Valley Fever - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Valley Fever - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Valley Fever - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Valley Fever - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Valley Fever - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Valley Fever - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Valley Fever - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Valley Fever - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Valley Fever - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Valley Fever - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Valley Fever - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Valley Fever - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Valley Fever - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Valley Fever - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Valley Fever - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Valley Fever - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Valley Fever - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Valley Fever - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Valley Fever - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Valley Fever - Access and Reimbursement Overview
16 VALLEY FEVER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 VALLEY FEVER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 VALLEY FEVER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 VALLEY FEVER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 VALLEY FEVER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 VALLEY FEVER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 VALLEY FEVER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 VALLEY FEVER - UNMET NEEDS
10 VALLEY FEVER - KEY ENDPOINTS OF TREATMENT
11 VALLEY FEVER - MARKETED PRODUCTS
11.1 List of Valley Fever Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 VALLEY FEVER - PIPELINE DRUGS
12.1 List of Valley Fever Pipeline Drugs Across the Top 7 Markets
12.1.1 VT 1598 - Mycovia Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. VALLEY FEVER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. VALLEY FEVER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 VALLEY FEVER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Valley Fever - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Valley Fever - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Valley Fever - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Valley Fever - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Valley Fever - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Valley Fever - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Valley Fever - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Valley Fever - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Valley Fever - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Valley Fever - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Valley Fever - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Valley Fever - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Valley Fever - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Valley Fever - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Valley Fever - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Valley Fever - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Valley Fever - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Valley Fever - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Valley Fever - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Valley Fever - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Valley Fever - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Valley Fever - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Valley Fever - Access and Reimbursement Overview
16 VALLEY FEVER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 VALLEY FEVER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 VALLEY FEVER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
